Recombinant factor VIIa (rFVIIa) after aortic valve replacement in a patient with osteogenesis imperfecta.
Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.
Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate.
Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial.
Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux.
Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair
Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease.
Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with hemophilia and inhibitors.
Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VII.
The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia.
The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa.
Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage. Blood Coagulation & Fibrinolysis.
Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use program in patients with severe hemophilia or with acquired inhibitors.
Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.
NovoSeven in warfarin-treated patients.
Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation.
Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
Clinical aspects of bleeding complications in cirrhotic patients.
Blood loss in orthotopic liver transplantation: a retrospective analysis of transfusion requirements and the effects of autotransfusion of cell saver blood in 164 consecutive patients.
Treatment of traumatic bleeding with recombinant factor VIIa.
Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII.
A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous hemorrhages in persons with hemophilia A and B, with and without inhibitors. rFVIIa Study Group.
Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia.
Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group.
Coagulation products and their uses.
The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders.
Successful use of recombinant VIIa (Novoseven) and endometrial ablation in a patient with intractable menorrhagia secondary to FVII deficiency.
Use of recombinant factor VIIa (NovoSeven®) to reduce postoperative bleeding after total hip arthroplasty in a patient with cirrhosis and thrombocytopenia.
Synthetic factor VIIa to treat dilutional coagulopathy during posterior spinal fusion in two children.
© Copyright 1999-2020 DocMD.com. All Rights Reserved.